Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma

SIMPLE SUMMARY: In relapsed, refractory B cell malignancies and multiple myeloma, chimeric antigen receptor (CAR) T cell therapy has represented a major scientific advancement with high response rates and durable responses for many. Nonetheless, target antigen downregulation in tumor cells can lead...

Descripción completa

Detalles Bibliográficos
Autores principales: Cronk, Robert J., Zurko, Joanna, Shah, Nirav N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564024/
https://www.ncbi.nlm.nih.gov/pubmed/32899464
http://dx.doi.org/10.3390/cancers12092523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564024/
https://www.ncbi.nlm.nih.gov/pubmed/32899464
http://dx.doi.org/10.3390/cancers12092523

Ejemplares similares